Tivic Health Systems, Inc. and its client recently completed a successful registered public offering, raising approximately $4 million in funds. The offering involved the sale of shares of common stock, Series A warrants, and Series B warrants at a public offering price of $0.85 per share and accompanying warrants.
The Series A warrants are immediately exercisable and will expire one year after the date of issuance, while the Series B warrants are also immediately exercisable and will expire five years after the date of issuance.
Tivic Health is a commercial health tech company that specializes in bioelectronic medicine. Their technology platform focuses on stimulating the trigeminal, sympathetic, and vagus nerve structures to provide non-invasive and targeted treatment for inflammatory chronic health conditions. ClearUP is their first commercial product, which is an FDA approved handheld bioelectronic sinus device that has been clinically proven and doctor-recommended. ClearUP offers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. It is available through online retailers and commercial distributors.
Christopher Tinen from Procopio Capital Markets & Securities practice led the transaction on behalf of Tivic Health, along with Senior Associate Caitlin Murphey and Associate Rachel Edwards.